This Community Hematology/Oncology Forums meeting series is designed to meet the educational needs of community- and academic-based hematologists, oncologists, and other health care professionals who treat patients with multiple myeloma.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
No specific specialties targeted.
Address:
- 384 Inverness Parkway
Pricing
All courses included · from $18.75/mo
Courses are included in the subscription; some are also sold individually.
| Student Flex | $18.75/mo |
| Professional Flex | $60/mo |
| Student 3-Year | $100 |
| Student 2-Year | $112.50 |
+4 more plans
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Surgical Oncology
- Thoracic Anesthesia
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- Credit · Up to 1 credit
- Commercial Support
-
Available fromOct 12, 2026
-
Last day to claim creditOct 13, 2027 1 year left
-
Plexus Communications +1 Beyond BCMA: Exploring GPRC5D-Directed CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma
-
Plexus Communications +1 Implementing CAR T-Cell Therapies for B-Cell Lymphoma in the Community Setting: Steps to Success Empowering Peer-to-Peer Education
-
Plexus Communications +1 Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
-
Physicians’ Education Resource Module 7: Multiple Myeloma (MM): Relapsed/Refractory Disease
-
PRIME Education, Inc. (PRIME®) GPRC5D-Targeted CAR T-Cell Therapies in Multiple Myeloma: Clinical Trial Updates and Implications of Recent Data
-
Integritas Communications CAR T-cell Therapy in MM Dialogue Between a MM Expert and a Community Oncologist
